SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).

ABSTRACT: The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal

SUBMITTER: Gonzalez Del Alba A 

PROVIDER: S-EPMC6339669 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature